Fundraising Fox3E Bioventures Capital — 2020 Investments
4 investments dated 2020 · listed companies and verified rows first · show all
Cytek Biosciences develops high-parametric analytical instruments and software that enable scientists at pharmaceutical companies, contract research organizations, and academic institutions to generate and analyze biological datasets.
BiotechDeep TechHardwareHealthtechMedical DevicesBellevue, US
Wenbin Jiang, Ph.D.(CEO and Chairman of the Board; co-founder)Wenbin Jiang(Executive Officer, Director)inMing Yan, Ph.D.(Chief Technology Officer; co-founder)Ming Yan(Executive Officer, Director)inJiecheng Zhang(Director)Allen Poirson(Director)
Co-investorsF-Prime CapitalNorthern Light Venture CapitalRA Capital
OncoC4 is a clinical-stage biopharmaceutical company developing immunotherapy treatments for cancer patients, based on research by its immunologist founders.
BiotechHealthtechRockville, US
Yang Liu(Co-founder)inPan Zheng(Co-founder)inMartin Devenport(Executive Officer)Michael Flaschen(Director)
Co-investorsHM Venture Partners
Subtle Computing (legally Skywalk, Inc.) makes wireless earbuds sold directly at subtle.co and through authorized resellers, along with a companion mobile app.
AI & Machine LearningConsumerDirect to ConsumerHardware
Tyler Chen(Founder)inDavid Harrison(Founder)Jackie Yang(Founder)Savannah Cofer(Founder)
Co-investorsAbstract VenturesEntrada VenturesInception Studio CapitalSLVCSurgePoint AngelBaidu Ventures+10 more
Subtle Medical develops deep learning software for medical imaging that enables faster and safer image acquisition on existing scanners for healthcare providers and imaging centers.
AI & Machine LearningHealthtechMedical Devices
Greg Zaharchuk(Co-founder, MD, Ph.D., Neuroradiologist and Professor at Stanford)inEnhao Gong(Co-founder, Ph.D., Deep Learning Scientist)in
Co-investorsAtinum Investment Co. Ltd.Bessemer Venture PartnersBreyer CapitalDCVC (Data Collective)Foothill VenturesFusion+11 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.